The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives—in particular, disease-modifying therapies (DMTs) that can slow the course of the disease. In response, drug developers—from big pharma to small biotech—continue to invest heavily in disease-modifying approaches due to the tremendous clinical and commercial opportunity in this arena, despite decades of late-phase failures. While, many uncertainties remain about the approval prospects for aducanumab, and the fate of anti-amyloid MAbs from Biogen / Eisai (BAN2401) and Roche (gantenerumab) in their ongoing Phase III trials, key opinion leaders (KOLs) are cautiously optimistic about the anti-tau therapies (approximately 15) in early- to mid-phase trials, and hope remains for the late-phase therapies from Lundbeck / Otsuka, Avanir / Otsuka, and Acadia that are in development for the treatment of AD agitation and psychosis, respectively. Ultimately, however, the launch of any of these is far from guaranteed.

QUESTIONS ANSWERED

  • What are the drivers and constraints in the AD market?
  • How large is the treatable AD population? What commercial uptake can be expected from Rexulti, AVP-786, and Nuplazid should they launch?
  • What will be the impact of DMTs—should any of them launch—on diagnosis, drug treatment, and revenue, and which populations will be most affected?
  • What are the key learning points from the recent failure of late-phase anti-amyloid therapies, and what are experts’ opinions of the launch prospects for agents still in development, such as Biogen / Eisai’s BAN2401?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Related Reports

Alzheimer's Disease - Landscape & Forecast - Disease Landscape & Forecast

The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open th...

View Details

Alzheimer's Disease - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

For the estimated 3.4 million people in the United States with Alzheimer’s disease (AD), approved pharmacotherapy is limited to four procognitive symptomatic agents (e.g., donepezil, memantin...

View Details